The article discusses the mechanisms of resistance to anti-angiogenic therapy, particularly in the context of vascular endothelial growth factor (VEGF) signaling pathways. It highlights two main modes of resistance: evasive resistance, which involves tumor adaptation to bypass the effects of anti-angiogenic drugs, and intrinsic resistance, which is pre-existing and independent of therapy. Evasive resistance can manifest through various mechanisms, including activation of alternative pro-angiogenic signaling pathways, recruitment of bone marrow-derived cells, increased pericyte coverage, and enhanced tumor invasion and metastasis. Intrinsic resistance may result from pre-existing tumor microenvironments that are resistant to angiogenesis inhibitors. The article also discusses the clinical applications of VEGF pathway inhibitors, such as bevacizumab, sorafenib, and sunitinib, and their limitations in providing long-term therapeutic benefits. Despite their initial efficacy, these drugs often fail to produce sustained clinical responses, leading to tumor regrowth and disease progression. The article emphasizes the need for further research to understand and overcome these resistance mechanisms, potentially through combination therapies targeting both angiogenesis and resistance pathways. It also highlights the importance of biomarkers and improved imaging techniques to assess the effectiveness of anti-angiogenic therapies and to identify patients who may benefit from them. The study underscores the complexity of tumor biology and the challenges in developing effective, long-lasting treatments for cancers that rely on angiogenesis for growth and survival.The article discusses the mechanisms of resistance to anti-angiogenic therapy, particularly in the context of vascular endothelial growth factor (VEGF) signaling pathways. It highlights two main modes of resistance: evasive resistance, which involves tumor adaptation to bypass the effects of anti-angiogenic drugs, and intrinsic resistance, which is pre-existing and independent of therapy. Evasive resistance can manifest through various mechanisms, including activation of alternative pro-angiogenic signaling pathways, recruitment of bone marrow-derived cells, increased pericyte coverage, and enhanced tumor invasion and metastasis. Intrinsic resistance may result from pre-existing tumor microenvironments that are resistant to angiogenesis inhibitors. The article also discusses the clinical applications of VEGF pathway inhibitors, such as bevacizumab, sorafenib, and sunitinib, and their limitations in providing long-term therapeutic benefits. Despite their initial efficacy, these drugs often fail to produce sustained clinical responses, leading to tumor regrowth and disease progression. The article emphasizes the need for further research to understand and overcome these resistance mechanisms, potentially through combination therapies targeting both angiogenesis and resistance pathways. It also highlights the importance of biomarkers and improved imaging techniques to assess the effectiveness of anti-angiogenic therapies and to identify patients who may benefit from them. The study underscores the complexity of tumor biology and the challenges in developing effective, long-lasting treatments for cancers that rely on angiogenesis for growth and survival.